» Articles » PMID: 24344134

PIASxα Ligase Enhances SUMO1 Modification of PTEN Protein As a SUMO E3 Ligase

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2013 Dec 18
PMID 24344134
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor suppressor PTEN plays a critical role in the regulation of multiple cellular processes that include survival, cell cycle, proliferation, and apoptosis. PTEN is frequently mutated or deleted in various human cancer cells to promote tumorigenesis. PTEN is regulated by SUMOylation, but the SUMO E3 ligase involved in the SUMOylation of PTEN remains unclear. Here, we demonstrated that PIASxα is a SUMO E3 ligase for PTEN. PIASxα physically interacted with PTEN both in vitro and in vivo. Their interaction depended on the integrity of phosphatase and C2 domains of PTEN and the region of PIASxα comprising residues 134-347. PIASxα enhanced PTEN protein stability by reducing PTEN ubiquitination, whereas the mutation of PTEN SUMO1 conjugation sites neutralized the effect of PIASxα on PTEN protein half-life. Functionally, PIASxα, as a potential tumor suppressor, negatively regulated the PI3K-Akt pathway through stabilizing PTEN protein. Overexpression of PIASxα led to G0/G1 cell cycle arrest, thus triggering cell proliferation inhibition and tumor suppression, whereas PIASxα knockdown or deficiency in catalytic activity abolished the inhibition. Together our studies suggest that PIASxα is a novel SUMO E3 ligase for PTEN, and it positively regulates PTEN protein level in tumor suppression.

Citing Articles

The impact of dysregulation SUMOylation on prostate cancer.

Li K, Wang H, Jiang B, Jin X J Transl Med. 2025; 23(1):286.

PMID: 40050932 PMC: 11887156. DOI: 10.1186/s12967-025-06271-2.


Protein inhibitor of activated signal transducer and activator of transcription 2 is an oncoprotein in oral squamous cell carcinoma and related to cigarette smoking - An in vitro study.

Chen S, Chiang C, Su Y, Lin C, Hung Y, Huang T J Dent Sci. 2024; 19(4):1983-1990.

PMID: 39347031 PMC: 11437306. DOI: 10.1016/j.jds.2024.07.013.


Post-Translational Modification of PTEN Protein: Quantity and Activity.

Li X, Yang P, Hou X, Ji S Oncol Rev. 2024; 18:1430237.

PMID: 39144161 PMC: 11321960. DOI: 10.3389/or.2024.1430237.


PIAS family in cancer: from basic mechanisms to clinical applications.

Li X, Rasul A, Sharif F, Hassan M Front Oncol. 2024; 14:1376633.

PMID: 38590645 PMC: 10999569. DOI: 10.3389/fonc.2024.1376633.


The SUMOylation and ubiquitination crosstalk in cancer.

Li K, Xia Y, He J, Wang J, Li J, Ye M J Cancer Res Clin Oncol. 2023; 149(17):16123-16146.

PMID: 37640846 DOI: 10.1007/s00432-023-05310-z.


References
1.
Sun H, Lesche R, Li D, Liliental J, Zhang H, Gao J . PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1999; 96(11):6199-204. PMC: 26859. DOI: 10.1073/pnas.96.11.6199. View

2.
Mabb A, Wuerzberger-Davis S, Miyamoto S . PIASy mediates NEMO sumoylation and NF-kappaB activation in response to genotoxic stress. Nat Cell Biol. 2006; 8(9):986-93. DOI: 10.1038/ncb1458. View

3.
Kakuguchi W, Kitamura T, Kuroshima T, Ishikawa M, Kitagawa Y, Totsuka Y . HuR knockdown changes the oncogenic potential of oral cancer cells. Mol Cancer Res. 2010; 8(4):520-8. DOI: 10.1158/1541-7786.MCR-09-0367. View

4.
Shen W, Balajee A, Wang J, Wu H, Eng C, Pandolfi P . Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007; 128(1):157-70. DOI: 10.1016/j.cell.2006.11.042. View

5.
Schmidt D, Muller S . PIAS/SUMO: new partners in transcriptional regulation. Cell Mol Life Sci. 2003; 60(12):2561-74. PMC: 11138616. DOI: 10.1007/s00018-003-3129-1. View